There has been a new article published in the Express newspaper today about how one of Celadon’s subsidiary companies LVL Health‘s game-changing trial is providing the best data set to date in the UK for the use of cannabis-based medicines for chronic pain. Celadon Pharmaceuticals Plc is the majority shareholder in LVL Health.
Chronic pain impacts an estimated 14-28 million people in the UK (depending on the estimate). Not only have cannabis-based medicines’ efficacy been seen widely across the world, but cannabis-based medicines could save the NHS money and relieve pressure. Chronic pain patients on average cost the NHS £15k annually through medications, consultations, doctor visits, pain clinics and A&E.